Table 1 Clinical characteristics of the 758 patients who underwent both fecal immunochemical test and total colonoscopy.
Characteristic | Anti-thrombotic agents | p-value | |
|---|---|---|---|
Yes (n = 144) | No (n = 614) | ||
Age (years); median (range) | 75 (46–92) | 63 (21–93) | < 0.0001 |
Gender-Male (% of Male) | 110 (76.4%) | 353 (57.5%) | < 0.0001 |
FIT positive/negative (positive ratio) | 71/73 (49.3%) | 296/318 (48.2%) | 0.7432 |
TCS finding | |||
Colorectal neoplasms | 61 (42.4%) | 217 (35.3%) | 0.1157 |
Colorectal cancer | 14 (9.7%) | 43 (7.0%) | 0.2655 |
Advanced adenoma | 15 (10.4%) | 56 (9.1%) | 0.6309 |
Non-advanced adenoma | 32 (22.2%) | 118 (19.2%) | 0.4155 |
Complication of life-style related diseases (%) | |||
Diabetes mellitus | 45 (31.3%) | 62 (10.1%) | < 0.0001 |
Hypertension | 90 (62.5%) | 206 (33.7%) | < 0.0001 |
Hyperlipidemia | 45 (31.3%) | 109 (17.8%) | 0.0003 |
Current medications (%) | |||
Antiplatelet | 129 (89.6%) | ||
Aspirin | 71 (49.3%) | ||
Thienopyridines | 29 (20.1%) | ||
Limaprost | 21(14.6%) | ||
Phosphodiesterase-3 inhibitors | 16 (11.1%) | ||
Eicosapentaenoic acid | 17 (11.8%) | ||
Dipyridamole | 6 (4.2%) | ||
Beraprost sodium | 1 (0.7%) | ||
Dilazep hydrochloride hydrate | 2 (1.4%) | ||
5-HT2 | 1 (0.7%) | ||
Anticoagulant | 22 (15.3%) | ||
Warfarin potassium | 14 (9.7%) | ||
DOAC | 8 (5.6%) | ||
